Topic: Compulsory License

Colombia plots 45% price cut on Novartis' Gleevec

A tense, months-long pricing standoff escalated late last week as Colombia announced plans to unilaterally move forward with a “public interest” measure that’ll cut the price of Novartis’ chronic myeloid leukemia med Gleevec there by about 45%.

Sanders chastises U.S. reps over role in Gleevec CL battle

Earlier this week, top lawmakers in the House of Representatives lambasted U.S. trade officials for allegedly pressuring the Colombian government to reject a compulsory license for Novartis’ cancer med Gleevec. Senate peers are also weighing in on the issue and chastising the officials for bad behavior.